What is the address of PR PHARMACEUTICALS?

The registered office of PR PHARMACEUTICALS is located at Langenberg 41, 2323 Hoogstraten.

Is PR PHARMACEUTICALS still active?

Yes. According to the CBE (31 October 2026) PR PHARMACEUTICALS is active, legal situation “Normale toestand”, started on 1 April 1999.

Is PR PHARMACEUTICALS registered on Peppol?

No, PR PHARMACEUTICALS is currently not registered on the Peppol network.

What is the enterprise number of PR PHARMACEUTICALS?

The enterprise number of PR PHARMACEUTICALS is BE0465770145.

When was PR PHARMACEUTICALS founded?

PR PHARMACEUTICALS was founded on 1 April 1999.

Who are the directors of PR PHARMACEUTICALS?

According to the 2025 annual accounts, the directors of PR PHARMACEUTICALS are: LUDO TIELEN.

Is PR PHARMACEUTICALS a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 1 April 1999; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did PR PHARMACEUTICALS make in 2025?

PR PHARMACEUTICALS recorded a loss after taxes of € 11,511 in financial year 2025.

What is the revenue of PR PHARMACEUTICALS?

As a small company, PR PHARMACEUTICALS is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -230.

PR PHARMACEUTICALS (Public Limited) - Hoogstraten

Q: What does PR PHARMACEUTICALS do?

PR PHARMACEUTICALS is registered with the CBE as active in: Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies. Public Limited, started on 1 April 1999, 1 establishment.

Dossier PR PHARMACEUTICALS, printed on 31 October 2026 from databakkes.be/en/0465770145/pr-pharmaceuticals. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 2 of the last 4 fiscal years.
Two loss years in a row NBB

Negative result in 2024 and 2025.
Tight liquidity NBB

Cash and receivables cover 6 % of short-term debt in 2025; threshold 65 %.
Busy address KBO

15 other companies have their registered office at the same address; threshold 10.
Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2025

PR PHARMACEUTICALS from Hoogstraten, company number BE0465770145, closed financial year 2025 with a result of € -11,511 after tax. For that financial year PR PHARMACEUTICALS recorded a gross margin of € -230 and equity of € -288,612. Compared with financial year 2024, the result moved from € -8,969 to € -11,511. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 20, 2026.

What it is worth Caution

€ -288,612

▼ € 11,511 vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -11,511

▼ 28 % more loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 31

▲ € 27 vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -354,867.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 57

▼ 61% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2024	2025	Change 2024 → 2025
Gross margin	€ 185 Gross margin 2021: € 185 First fiscal year in the series	€ -710 Gross margin 2022: € -710 ▼ € 894 vs 2021 (€ 185) Unfavourable step	€ -208 Gross margin 2024: € -208 ▲ € 502 vs 2022 (€ -710) Favourable step	€ -230 Gross margin 2025: € -230 ▼ € 23 vs 2024 (€ -208) Unfavourable step	▼ € 23
Profit after taxes	€ 1,697 Profit after taxes 2021: € 1,697 First fiscal year in the series	€ 3,527 Profit after taxes 2022: € 3,527 ▲ 108% vs 2021 (€ 1,697) Favourable step	€ -8,969 Profit after taxes 2024: € -8,969 ▼ € 12,495 vs 2022 (€ 3,527) Unfavourable step	€ -11,511 Profit after taxes 2025: € -11,511 ▼ € 2,542 vs 2024 (€ -8,969) Unfavourable step	▼ € 2,542
Equity	€ 183,634 Equity 2021: € 183,634 First fiscal year in the series	€ 187,161 Equity 2022: € 187,161 ▲ 2% vs 2021 (€ 183,634) Favourable step	€ -277,101 Equity 2024: € -277,101 ▼ € 464,262 vs 2022 (€ 187,161) Unfavourable step	€ -288,612 Equity 2025: € -288,612 ▼ € 11,511 vs 2024 (€ -277,101) Unfavourable step	▼ € 11,511
Total debts	€ 14,235 Total debts 2021: € 14,235 First fiscal year in the series	€ 13,648 Total debts 2022: € 13,648 ▼ 4% vs 2021 (€ 14,235) Favourable step	€ 296,264 Total debts 2024: € 296,264 ▲ € 282,616 vs 2022 (€ 13,648) Unfavourable step	€ 308,292 Total debts 2025: € 308,292 ▲ 4% vs 2024 (€ 296,264) Unfavourable step	▲ 4%
Cash	€ 572 Cash 2021: € 572 First fiscal year in the series	€ 76 Cash 2022: € 76 ▼ 87% vs 2021 (€ 572) Unfavourable step	€ 3 Cash 2024: € 3 ▼ 95% vs 2022 (€ 76) Unfavourable step	€ 31 Cash 2025: € 31 ▲ € 27 vs 2024 (€ 3) Favourable step	▲ € 27
Retained profit	€ -352,621 Retained profit 2021: € -352,621 First fiscal year in the series	€ -349,095 Retained profit 2022: € -349,095 ▲ € 3,527 vs 2021 (€ -352,621) Favourable step	€ -343,357 Retained profit 2024: € -343,357 ▲ € 5,738 vs 2022 (€ -349,095) Favourable step	€ -354,867 Retained profit 2025: € -354,867 ▼ € 11,511 vs 2024 (€ -343,357) Unfavourable step	▼ € 11,511
Bank debt	€ 0 Bank debt 2021: € 0 First fiscal year in the series	€ 0 Bank debt 2022: € 0 Unchanged (€ 0) Unchanged	€ 1 Bank debt 2024: € 1 Unchanged (€ 0) Unfavourable step	€ 0 Bank debt 2025: € 0 ▼ 100% vs 2024 (€ 1) Favourable step	▼ 100%
Balance sheet total	€ 197,869 Balance sheet total 2021: € 197,869 First fiscal year in the series	€ 200,809 Balance sheet total 2022: € 200,809 ▲ 1% vs 2021 (€ 197,869) Unchanged	€ 19,162 Balance sheet total 2024: € 19,162 ▼ 90% vs 2022 (€ 200,809) Unchanged	€ 19,680 Balance sheet total 2025: € 19,680 ▲ 3% vs 2024 (€ 19,162) Unchanged	▲ 3%

Key figures of PR PHARMACEUTICALS, fiscal years 2021 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PR PHARMACEUTICALS?

What happened at PR PHARMACEUTICALS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2027 LUDO TIELEN stepped down as director. NBB
Jul 20, 2026 New annual accounts for financial year 2025: loss of € 11,511. Source: NBB ↗
2021 LUDO TIELEN became a director. NBB
Jul 19, 1999 New establishment in Hoogstraten. KBO
Apr 1, 1999 Start of the company according to the CBE. KBO

In short

From € 1,697 profit in 2021 to € 11,511 loss in 2025.

Paid € 4,063 in corporate taxes since 2021.

Best year ever: 2022, with € 3,527 profit.

Original PDFs at the National Bank ↗

Management

Directors

According to the 2025 annual accounts

LUDO TIELEN

Managing director

Also active at: Intermedia, YACELO, R.W.H., EASTERN, HMK-HOLTRANS, PHARMATEL, Pharmatel-Immo, Oversea Invest +2 more

since 2021 · until 2027

Establishments

Establishment units

Physical locations of this company

Registered office

Langenberg 41

2323 Hoogstraten

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 15 companies are registered at this address.

All companies at this address →

Intermedia same network

€ 4,003 gross margin · 2025

YACELO same network

€ -462,890 gross margin · 2025

I.D. Vastgoed

€ 51,084 gross margin · 2025

'T HOFKE

€ -1,879 gross margin · 2025

R.W.H. same network

€ -347 gross margin · 2025

+10 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0465.770.145

VAT number

BE 0465.770.145

Registered office

Langenberg 41, 2323 Hoogstraten

Names & denominations

PR PHARMACEUTICALS · PRP

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

1 April 1999

Peppol

Not registered

Activities · NACE

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsvoering en beheer

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

View on CBE Public ↗ Annual accounts (NBB) ↗

PR PHARMACEUTICALS